Phaseline

Targets › NR3C4

NR3C4 (Androgen receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Genitourinary, Other; next expected readout Dec 2026.

Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling…. (UniProt, P10275)

Open in Phaseline: the race on NR3C4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boehringer IngelheimBI 690517
Finerenone-like non-steroidal mineralocorticoid receptor antagonist
NR3C4Phase 3Kidney Disease, ChronicDec 2026
Pr. Nicolas GIRERDPotassium Canrenoate
Mineralocorticoid receptor (MR) antagonist
NR3C4Phase 2Brain-dead Organ DonorsDec 2033

Conditions

Kidney Disease, Chronic (1) Brain-dead Organ Donors (1)

Modalities

small molecule (2)

Companies

Boehringer Ingelheim (1) Pr. Nicolas GIRERD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.